Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge

References

• Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur. J. Cancer42(2), 126–140 (2006).
   PubMed Web of Science ®Google Scholar
• Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist7(4), 279–287 (2002).
   PubMed Web of Science ®Google Scholar
• Azim HA Jr, Peccatori FA. Treatment of cancer during pregnancy: the need for tailored strategies. J. Clin. Oncol.28(18), e302–e303; author reply e304 (2010).
   PubMed Web of Science ®Google Scholar
• Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol.5(5), 283–291 (2004).
   PubMed Web of Science ®Google Scholar
• Azim HA Jr, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors. Cancer Treat. Rev.36(2), 110–121 (2010).
   PubMed Web of Science ®Google Scholar
• Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat. Rev.36(2), 101–109 (2010).
   PubMed Web of Science ®Google Scholar
• Robinson AA, Watson WJ, Leslie KK. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol.8(8), 738–743 (2007).
   PubMed Web of Science ®Google Scholar
• Mix E, Goertsches R, Zett UK. Immunoglobulins – basic considerations. J. Neurol.253(Suppl. 5), V9–V17 (2006).
   PubMedGoogle Scholar
• Simister NE. Placental transport of immunoglobulin G. Vaccine21(24), 3365–3369 (2003).
   PubMed Web of Science ®Google Scholar
• Congy-Jolivet N, Probst A, Watier H, Thibault G. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit. Rev. Oncol. Hematol.64(3), 226–233 (2007).
   PubMed Web of Science ®Google Scholar
• Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev. Reprod.4(2), 81–89 (1999).
   PubMedGoogle Scholar
• Takizawa T, Anderson CL, Robinson JM. A novel FcgR-defined, IgG-containing organelle in placental endothelium. J. Immunol.175(4), 2331–2339 (2005).
   PubMed Web of Science ®Google Scholar
• Malek A. Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine21(24), 3362–3364 (2003).
   PubMed Web of Science ®Google Scholar
• Israel EJ, Simister N, Freiberg E, Caplan A, Walker WA. Immunoglobulin G binding sites on the human foetal intestine: a possible mechanism for the passive transfer of immunity from mother to infant. Immunology79(1), 77–81 (1993).
   PubMed Web of Science ®Google Scholar
• Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. B. Dev. Reprod. Toxicol.86(4), 328–344 (2009).
   PubMed Web of Science ®Google Scholar
• Gurevich P, Elhayany A, Ben-Hur H et al. An immunohistochemical study of the secretory immune system in human fetal membranes and decidua of the first trimester of pregnancy. Am. J. Reprod. Immunol.50(1), 13–19 (2003).
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol. Diversity10(4), 515–527 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature380(6573), 439–442 (1996).
   PubMed Web of Science ®Google Scholar
• Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J.14(3), 170–177 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res.55, 15–35; discussion 35–16 (2000).
   PubMedGoogle Scholar
• Demir R, Seval Y, Huppertz B. Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem.109(4), 257–265 (2007).
   PubMed Web of Science ®Google Scholar
• Pauli SA, Tang H, Wang J et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology146(3), 1301–1311 (2005).
   PubMed Web of Science ®Google Scholar
• Cheung CY. Vascular endothelial growth factor activation of intramembranous absorption: a critical pathway for amniotic fluid volume regulation. J. Soc. Gynecol. Invest.11(2), 63–74 (2004).
   PubMedGoogle Scholar
• Leck IM, Millar EL. Incidence of malformations since the introduction of thalidomide. Br. Med. J.2(5296), 16–20 (1962).
   PubMed Web of Science ®Google Scholar
• Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol.59(12), 1489–1499 (2000).
   PubMed Web of Science ®Google Scholar
• Demir R, Kayisli UA, Seval Y et al. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta25(6), 560–572 (2004).
   PubMed Web of Science ®Google Scholar
• Patyna S, Haznedar J, Morris D et al. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res.86(3), 204–213 (2009).
   Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev.6(8), 465–477 (2009).
   Google Scholar
• Berkane N. [Gestational hypertensions: definitions and consequences in outcome of pregnancy]. Ann. Fr. Anesth. Reanim.29(3), e1–e6 (2010).
   PubMedGoogle Scholar
• Wu Z, Huang J, Sadda S. Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann. Acad. Med. Singapore39(2), 143–145 (2010).
   PubMed Web of Science ®Google Scholar
• Rosen E, Rubowitz A, Ferencz JR. Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye23(6), 1479 (2009).
   PubMed Web of Science ®Google Scholar
• Petrou P, Georgalas I, Giavaras G et al. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmologica88(4), e136 (2010).
   PubMed Web of Science ®Google Scholar
• Azim H, Azim HA Jr. Targeting Her-2/neu in breast cancer: as easy as this! Oncology74(3–4), 150–157 (2008).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer116(4), 791–798 (2010).
   PubMed Web of Science ®Google Scholar
• Lee KF, Simon H, Chen H et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature378(6555), 394–398 (1995).
   PubMed Web of Science ®Google Scholar
• Negro A, Brar BK, Gu Y et al. ErbB2 is required for G protein-coupled receptor signaling in the heart. Proc. Natl Acad. Sci. USA103(43), 15889–15893 (2006).
   PubMed Web of Science ®Google Scholar
• Azim H, Azim HA Jr, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat. Rev.35(7), 633–638 (2009).
   PubMed Web of Science ®Google Scholar
• Waterston AM, Graham J. Effect of adjuvant trastuzumab on pregnancy. J. Clin. Oncol.24(2), 321–322 (2006).
   PubMed Web of Science ®Google Scholar
• Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet. Gynecol.105(3), 642–643 (2005).
   PubMed Web of Science ®Google Scholar
• Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin. Breast Cancer6(4), 354–356 (2005).
   PubMedGoogle Scholar
• Bader AA, Schlembach D, Tamussino KF, Pristauz G, Petru E. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol.8(1), 79–81 (2007).
   PubMed Web of Science ®Google Scholar
• Shrim A, Garcia-Bournissen F, Maxwell C, Farine D, Koren G. Favorable pregnancy outcome following trastuzumab (Herceptin) use during pregnancy – case report and updated literature review. Reprod. Toxicol.23(4), 611–613 (2007).
   PubMed Web of Science ®Google Scholar
• Sekar R, Stone PR. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet. Gynecol.110(2 Pt 2), 507–510 (2007).
   PubMed Web of Science ®Google Scholar
• Witzel ID, Muller V, Harps E, Janicke F, Dewit M. Trastuzumab in pregnancy associated with poor fetal outcome. Ann. Oncol.19(1), 191–192 (2008).
   PubMed Web of Science ®Google Scholar
• Berveiller P, Mir O, Sauvanet E, Antoine EC, Goldwasser F. Ectopic pregnancy in a breast cancer patient receiving trastuzumab. Reprod. Toxicol.25(2), 286–288 (2008).
   PubMed Web of Science ®Google Scholar
• Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J. Clin. Oncol.26(9), 1567–1569 (2008).
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Schaefer C. Trastuzumb exposure during pregnancy. Reprod. Toxicol.25(3), 390–391; author reply 392 (2008).
   PubMed Web of Science ®Google Scholar
• Azim HA Jr, Peccatori FA, Liptrott SJ, Catania C, Goldhirsch A. Breast cancer and pregnancy: how safe is trastuzumab? Nat. Rev.6(6), 367–370 (2009).
   Google Scholar
• Goodyer MJ, Ismail JR, O’Reilly SP et al. Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J.2, 9329 (2009).
   PubMedGoogle Scholar
• Warraich Q, Smith N. Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J. Obstet. Gynaecol.29(2), 147–148 (2009).
   PubMedGoogle Scholar
• Beale JM, Tuohy J, McDowell SJ. Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am. J. Obstet. Gynecol.201(1), e13–e14 (2009).
   PubMed Web of Science ®Google Scholar
• Kokai Y, Cohen JA, Drebin JA, Greene MI. Stage- and tissue-specific expression of the neu oncogene in rat development. Proc. Natl Acad. Sci. USA84(23), 8498–8501 (1987).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J. Clin. Oncol.28(17), 2853–2858 (2010).
   PubMed Web of Science ®Google Scholar
• Cordeiro A, Machado AI, Borges A, Alves MJ, Frade MJ. Burkitt’s lymphoma related to Epstein–Barr virus infection during pregnancy. Arch. Gynecol. Obstet.280(2), 297–300 (2009).
   PubMed Web of Science ®Google Scholar
• Rey J, Coso D, Roger V et al. Rituximab combined with chemotherapy for lymphoma during pregnancy. Leukemia Res.33(3), e8–e9 (2009).
   PubMedGoogle Scholar
• Decker M, Rothermundt C, Hollander G, Tichelli A, Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol.7(8), 693–694 (2006).
   PubMed Web of Science ®Google Scholar
• Magloire LK, Pettker CM, Buhimschi CS, Funai EF. Burkitt’s lymphoma of the ovary in pregnancy. Obstet. Gynecol.108(3 Pt 2), 743–745 (2006).
   PubMed Web of Science ®Google Scholar
• Friedrichs B, Tiemann M, Salwender H et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica91(10), 1426–1427 (2006).
   PubMed Web of Science ®Google Scholar
• Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J. Clin. Oncol.19(14), 3439 (2001).
   PubMed Web of Science ®Google Scholar
• Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur. J. Hematol.72(4), 292–295 (2004).
   PubMed Web of Science ®Google Scholar
• Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin. Dev. Immunol.2008, 271363 (2008).
   PubMedGoogle Scholar